Skip to main content

Table 4 ABC length of sulforaphane (SF) exposure analysis

From: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

ABC variable Intervention (SF)a Non-exposure (PL)
N F-statistic p value N F-statistic p value
Total score
 7 weeks 38 9.59 0.004 21 4.76 0.041
 15 weeks 34 12.74 0.001 18 2.02 0.166
 22 weeks 16 5.05 0.016    
 30 weeks 12 2.22 0.156    
Sqrt lethargyb
 7 weeks 38 1.55 0.221 21 2.94 0.102
 15 weeks 34 4.75 0.016 18 1.68 0.218
 22 weeks 16 4.20 0.028    
 30 weeks 12 2.06 0.179    
Sqrt irritability
 7 weeks 38 6.06 0.019 21 2.27 0.147
 15 weeks 34 9.27 0.001 18 0.87 0.436
 22 weeks 16 4.03 0.032    
 30 weeks 12 2.06 0.179    
Sqrt stereotypy
 7 weeks 38 4.85 0.034 21 1.74 0.202
 15 weeks 34 6.06 0.006 18 1.72 0.210
 22 weeks 16 1.22 0.343    
 30 weeks 12 0.75 0.588    
Hyperactivity
 7 weeks 38 9.62 0.004 21 10.15 0.005
 15 weeks 34 9.95 < 0.001 18 4.68 0.025
 22 weeks 16 5.36 0.013    
 30 weeks 12 3.26 0.073    
Inappropriate speech
 7 weeks 38 7.85 0.008 21 0.27 0.607
 15 weeks 33 4.11 0.026 18 0.11 0.894
 22 weeks 16 3.02 0.068    
 30 weeks 12 1.95 0.196    
  1. Bold signifies p < 0.05
  2. MANOVA test for repeated measures
  3. aN for SF group at 7 and 15 weeks includes participants from the initial PL group while they were on SF at 22 and 30 weeks (their first 7 and 15 weeks of exposure)
  4. bSqrt: Square root transformations were conducted on these biomarkers to achieve a more normal distribution